| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825734 | Clinical Therapeutics | 2011 | 12 Pages |
Abstract
In this selected population of adults with type 2 diabetes, the fenofibrate/pravastatin 160/40 mg FDC was associated with significantly greater changes from baseline in non-HDL-C, triglyceride, and HDL-C concentrations compared with simvastatin 20 mg. Both treatments were well tolerated.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Michel MD, PhD, Armin MD, Kjetil MD, PhD, Albert MD, DSc,